The PNI is commonly used as a prognostic factor for malignant tumors, but its potential use for prostate cancer is unknown. Results of the BOP trial have shown 64Cu SAR-Bombesin can detect lesions in BCR prostate cancer that is PSMA PET-negative. Utilizing BCR as a replacement measurement for OS in patients with localized prostate cancer is a controversial topic. The FDA may allow the temporary use of drugs from overseas to alleviate the ongoing cisplatin and carboplatin shortages. SNMMI convened an autonomous workgroup to review prospective phase 2/3 clinical trials that used 177Lu-PSMA-617. The da Vinci Single Port platform allows robot-assisted surgical procedures with the same precision as multiport techniques. Increasing competition in robot-assisted surgical platform production will increase accessibility for patients everywhere. A PSA decrease ≥30% after the first 2 cycles of 177Lu PSMA can serve as an early marker of response in clinical practice. As mCRPC cells are deficient in retinoblastoma proteins, they have a hypersensitivity to taxanes such as cabazitaxel. Dr. Scott Eggener provides an overview of the advancements in and patient perspectives on Grade Group 1 prostate cancer. Multiple genitourinary oncology therapies are in the spotlight this week, with new US FDA indications on the horizon. The trial’s 2 primary end points were PFS and overall survival, with a secondary end point of objective response rate. The SOLAR trial aimed to evaluate the safety and biodistribution of Copper Cu 64 PSMA I&T to detect prostate cancer. Drs. Marshall, Reimers, and Dorff discuss toxicities from single-agent and combination-based HR inhibitors. Drs. Marshall, Reimers, and Dorff discuss PARP inhibitor strategies for BRCA-mutated patients throughout the care continuum. Foundation Medicine’s comprehensive genomic profiling test identifies mCRPC harboring BRCA1/2-positive mutations. The phase 3 TITAN study assigned patients with mCSPC apalutamide or placebo with ADT to determine its effects on PFS and OS. A facility’s case volume of patients with VHR PCa is independently associated with longer OS in this patient group. The FDA granted approval to AKEEGA given with prednisone for patients with BRCA-positive mCRPC. Patients with a suboptimal PSA response who are administered intensified ADT often experience worse survival outcomes.